This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the promotion of Mark Shepanski to Executive Director of Operations and Site Lead of its San Diego facilities. In his new role as executive director at PCI, Mark will ensure that the San Diego Center of Excellence continues to deliver on its reputation for fast, flexible, and reliable clinical services. The site features dynamic services focused on packaging, labeling, and logistical support activities for investigational drug products including advanced Cold Chain logistics for global clinical studies.
With extensive industry experience, Mark had previously led operational and quality teams at Sherpa Clinical Packaging, which was officially acquired by PCI on October 1, 2018. Most recently, he was the Senior Director of Quality at Sherpa. He has over 17 years of experience leading operational and quality teams.
Mark will report to Brad Payne, PCI’s Senior Vice President of Global Operations. Commenting on the appointment, Brad noted: “Mark brings valuable experience from his years at Sherpa, and his considerable experience in diverse sectors of the biopharmaceutical and medical device industries. His commitment to advancing our operational processes and expert team at the San Diego site will be instrumental to ensuring that our customers continue to receive best-in-class clinical services.”
“PCI’s expanded clinical supply services, coupled with our global reach through investments at sites across the U.S., Europe, and Asia Pacific regions, are critical strategic initiatives that will aid our clinical customers in successfully managing their global studies,” stated Mark. “I foresee exciting capability expansion possibilities at our San Diego location as we continue to develop a comprehensive global suite of services to help our clients bring their molecule to market. I look forward to driving the operational processes here that will support the fast, flexible, and reliable clinical services that our clients expect.”
PCI has continued to actively invest in its global clinical services portfolio, with the Sherpa acquisition being the third in the past 12 months. In October 2017, PCI acquired contract packaging services provider Millmount Healthcare based in Dublin, Ireland. Later in March 2018, PCI acquired Pharmaceutical Packaging Professionals in Melbourne, Australia, bolstering its capability for early phase clinical study as well as adding new clinical scale drug manufacture capabilities, including sterile and non-sterile delivery forms. PCI’s expanded reach strengthens its position as a global leader in the pharmaceutical packaging industry and partner of choice for pharmaceutical and biotech companies around the world.
To find out more about PCI, please visit here.
